CILK1 and breast carcinoma: We used a panel of breast cancer cell lines, including MDA-MB-231 and BT-549 (Triple-negative), T47D (Luminal) and BT-474 (HER2+) to construct stable CILK1-knockdown clones (Fig. S2A).